“Improving prescription drug affordability for Medicare enrollees is the core of the Inflation Reduction Act, and the next cycle of negotiations will continue to strengthen Medicare for generations to come," Chiquita Brooks-LaSure, administrator of the Centers for Medicare & Medicaid Services, said in the news release.

Concern is growing among Democrats after President Donald Trump reversed some of the former president's executive orders, including efforts to reduce prescription drug costs for Medicare and Medicaid beneficiaries.

The new Trump administration should seize the opportunity to change the Medicare drug price negotiation program by introducing floors.

Drug pricing experts are not sure why rolling back drug pricing initiatives would be a day one priority for President Trump.

Trump’s executive order halts an effort to cap the copayment for generic medications at $2 for Medicare beneficiaries.

Trump has reversed some of President Biden’s initiatives, including $2 monthly out-of-pocket cap on some generics and experimental pricing models for gene therapies. But so far the healthcare elements of the Inflation Reduction Act remain unchanged.

Experts suggest that most Americans will not experience immediate changes in their out-of-pocket health care expenses.

The rescinded order directed Medicare and Medicaid to test ways to lower drug costs for enrollees. Those tests hadn’t started, so current drug prices are unaffected.

One of those now-cancelled policies directed Medicare to investigate ways to slash drug costs, including the possibility of a $2 monthly out-of-pocket cap on some generic medications. Monday's actions also follow through on a key goal of Trump's first term -- weakening the Affordable Care Act.